FY2019 Earnings Estimate for Edwards Lifesciences Corporation Issued By Leerink Swann (EW)

Edwards Lifesciences Corporation (NYSE:EW) – Leerink Swann lowered their FY2019 EPS estimates for Edwards Lifesciences Corporation in a report issued on Tuesday. Leerink Swann analyst D. Antalffy now expects that the medical research company will post earnings per share of $4.44 for the year, down from their prior estimate of $4.45. Leerink Swann also issued estimates for Edwards Lifesciences Corporation’s FY2020 earnings at $5.09 EPS and FY2021 earnings at $5.88 EPS.

Edwards Lifesciences Corporation (NYSE:EW) last announced its quarterly earnings data on Wednesday, July 26th. The medical research company reported $1.08 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.88 by $0.20. Edwards Lifesciences Corporation had a return on equity of 27.17% and a net margin of 22.16%. The company had revenue of $842.00 million for the quarter, compared to analyst estimates of $839.16 million. During the same quarter in the previous year, the company earned $0.76 EPS. The firm’s revenue for the quarter was up 10.9% compared to the same quarter last year.

COPYRIGHT VIOLATION NOTICE: “FY2019 Earnings Estimate for Edwards Lifesciences Corporation Issued By Leerink Swann (EW)” was first posted by Markets Daily and is the property of of Markets Daily. If you are accessing this piece of content on another site, it was stolen and republished in violation of international copyright and trademark law. The legal version of this piece of content can be accessed at https://www.themarketsdaily.com/2017/10/12/fy2019-earnings-estimate-for-edwards-lifesciences-corporation-issued-by-leerink-swann-ew.html.

Other equities research analysts have also issued research reports about the stock. Royal Bank Of Canada restated a “buy” rating and issued a $130.00 price target on shares of Edwards Lifesciences Corporation in a research note on Friday, July 28th. Stifel Nicolaus restated a “buy” rating and issued a $130.00 price target (up previously from $118.00) on shares of Edwards Lifesciences Corporation in a research note on Thursday, July 27th. Zacks Investment Research upgraded shares of Edwards Lifesciences Corporation from a “hold” rating to a “buy” rating and set a $130.00 price target on the stock in a research note on Tuesday, July 18th. SunTrust Banks, Inc. raised their price target on shares of Edwards Lifesciences Corporation to $14.00 and gave the company a “buy” rating in a research note on Monday, July 17th. Finally, Jefferies Group LLC raised their price target on shares of Edwards Lifesciences Corporation from $115.00 to $132.00 and gave the company a “buy” rating in a research note on Thursday, July 27th. Seven research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has given a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $120.75.

Shares of Edwards Lifesciences Corporation (NYSE:EW) traded down 0.182% during midday trading on Thursday, reaching $110.269. The company’s stock had a trading volume of 435,368 shares. The stock has a 50 day moving average of $111.59 and a 200-day moving average of $111.24. Edwards Lifesciences Corporation has a 1-year low of $81.12 and a 1-year high of $121.45. The company has a market capitalization of $23.43 billion, a P/E ratio of 42.249 and a beta of 0.62.

Institutional investors have recently bought and sold shares of the stock. ETF Managers Group LLC acquired a new position in Edwards Lifesciences Corporation in the 2nd quarter worth approximately $112,000. Shine Investment Advisory Services Inc. acquired a new position in Edwards Lifesciences Corporation in the 2nd quarter worth approximately $126,000. Cornerstone Advisors Inc. boosted its stake in Edwards Lifesciences Corporation by 25.1% in the 2nd quarter. Cornerstone Advisors Inc. now owns 1,092 shares of the medical research company’s stock worth $129,000 after purchasing an additional 219 shares during the period. Alexandria Capital LLC boosted its stake in Edwards Lifesciences Corporation by 1.7% in the 2nd quarter. Alexandria Capital LLC now owns 1,146 shares of the medical research company’s stock worth $136,000 after purchasing an additional 19 shares during the period. Finally, MPS Loria Financial Planners LLC acquired a new position in Edwards Lifesciences Corporation in the 2nd quarter worth approximately $140,000. 82.12% of the stock is owned by hedge funds and other institutional investors.

In related news, VP Donald E. Bobo, Jr. sold 5,300 shares of the firm’s stock in a transaction that occurred on Friday, July 28th. The shares were sold at an average price of $114.68, for a total transaction of $607,804.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Catherine M. Szyman sold 4,681 shares of the firm’s stock in a transaction that occurred on Monday, July 31st. The stock was sold at an average price of $115.78, for a total transaction of $541,966.18. The disclosure for this sale can be found here. Insiders have sold 182,201 shares of company stock valued at $20,768,154 over the last 90 days. 2.13% of the stock is currently owned by insiders.

Edwards Lifesciences Corporation Company Profile

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Earnings History and Estimates for Edwards Lifesciences Corporation (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply